During WCLC 2024, Dr. Patrick Forde presented data from the CheckMate 77T and CheckMate 816 trials that may help guide lung cancer management in the near future. Read more
Results from the study, presented by Dr. Jin-Ji Yang, suggest that a combination regimen of osimertinib plus savolitinib may be superior to osimertinib alone for EGFR-mutated NSCLC. Read more
Fulzerasib becomes the first KRAS G12C inhibitor approved in China. Encorafenib receives approval from the European Commission. The US FDA grants priority review and breakthrough therapy designation to durvalumab for SCLC. Read more
A novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC. Read more
Furmonertinib, an oral, brain-penetrant, mutation-selective EGFR TKI, demonstrates activity in patients with EGFR PACC mutations. Read more
The third-generation EGFR TKI joins osimertinib in demonstrating a meaningful progression-free survival benefit for consolidation following chemoradiation. Read more
Experts will focus on overcoming barriers in patient advocacy on a global basis and enhancing the patient-physician partnership. Read more
Tuesday morning, nine expert clinicians and researchers in the field will give award lectures in honor of their contributions to the treatment of lung cancer. Read more
Drs. Narjust Florez and Cecilia Pompili will co-chair the session, which will also include tips for improving inclusion in clinical trials, creating a mutually respective work environment, and more. Read more
The association’s most prestigious award was presented to five multidisciplinary teams from around the world during the IASLC Award Ceremony. Read more